Eriya Kenjo
Research Subjects
Eriya Kenjo has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Akitsu Hotta
Department of Clinical Application, Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan
1 shared publication Hiroyuki Hozumi
T-CiRA discovery, Takeda Pharmaceutical Company Limited, Fujisawa, Japan
1 shared publicationKumiko A. Iwabuchi
Takeda-CiRA Joint Program, Fujisawa, Japan
1 shared publicationMasataka Ifuku
Takeda-CiRA Joint Program, Fujisawa, Japan
1 shared publicationMaya Kimura
Drug Safety Research and Evaluation, Takeda Pharmaceutical Company Limited, Fujisawa, Japan
1 shared publicationNaoko Fujimoto
Takeda-CiRA Joint Program, Fujisawa, Japan
1 shared publication
Latest Publications
- Top Cited PapersOpen Access
- 8 December 2021
- Published by Springer Nature in Nature Communications
- Vol. 12 (1) , 1-13
Low immunogenicity of LNP allows repeated administrations of CRISPR-Cas9 mRNA into skeletal muscle in mice
Genome editing therapy for Duchenne muscular dystrophy (DMD) holds great promise, however, one major obstacle is delivery of the CRISPR-Cas9/sgRNA system to skeletal muscle tissues. In general, AAV vectors are used for in vivo delivery, but AAV injections cannot be repeated because of neutralization antibodies. Here we report a chemically defined lipid nanoparticle (LNP) system which is able to deliver Cas9 mRNA and sgRNA into skeletal muscle by repeated intramuscular injections. Although the expressions of Cas9 protein and sgRNA were transient, our LNP system could induce stable genomic exon skipping and restore dystrophin protein in a DMD mouse model that harbors a humanized exon sequence. Furthermore, administration of our LNP via limb perfusion method enables to target multiple muscle groups. The repeated administration and low immunogenicity of our LNP system are promising features for a delivery vehicle of CRISPR-Cas9 to treat skeletal muscle disorders.
- 8 December 2021
- Published by Springer Nature in Nature Communications
- Vol. 12 (1) , 1-13
Top Cited PapersOpen AccessLow immunogenicity of LNP allows repeated administrations of CRISPR-Cas9 mRNA into skeletal muscle in mice
Genome editing therapy for Duchenne muscular dystrophy (DMD) holds great promise, however, one major obstacle is delivery of the CRISPR-Cas9/sgRNA system to skeletal muscle tissues. In general, AAV vectors are used for in vivo delivery, but AAV injections cannot be repeated because of neutralization antibodies. Here we report a chemically defined lipid nanoparticle (LNP) system which is able to deliver Cas9 mRNA and sgRNA into skeletal muscle by repeated intramuscular injections. Although the expressions of Cas9 protein and sgRNA were transient, our LNP system could induce stable genomic exon skipping and restore dystrophin protein in a DMD mouse model that harbors a humanized exon sequence. Furthermore, administration of our LNP via limb perfusion method enables to target multiple muscle groups. The repeated administration and low immunogenicity of our LNP system are promising features for a delivery vehicle of CRISPR-Cas9 to treat skeletal muscle disorders.